

NHS Grampian Formulary Group Decisions for SMC advice published April 2026



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2026.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

April 2026

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
acalabrutinib 100mg film-coated tablets (Calquence®)	2893	In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: acalabrutinib in combination with venetoclax only.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
baloxavir marboxil 40mg, 80mg film-coated tablets (Xofluza®)	2920	Treatment of uncomplicated influenza in patients aged 3 weeks and above.	Not routinely available as not recommended for use in NHS Scotland, SMC 2920 https://scottishmedicines.org.uk/media/9972/baloxavir-marboxil-xofluza-smc2920-non-sub-final-march-2026-for-website.pdf	21/04/2026
baloxavir marboxil 40mg, 80mg film-coated tablets (Xofluza®)	2921	Post-exposure prophylaxis of influenza in individuals aged 3 weeks and above.	Not routinely available as not recommended for use in NHS Scotland, SMC 2921 https://scottishmedicines.org.uk/media/9973/baloxavir-marboxil-xofluza-smc2921-non-sub-final-march-2026-for-website.pdf	21/04/2026
dostarlimab 500mg concentrate for solution for infusion (Jemperli®)	2828	In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2828 https://scottishmedicines.org.uk/media/9974/dostarlimab-jemperli-final-march-2026-for-website.pdf	21/04/2026
eszopiclone 1mg, 2mg, 3mg film-coated tablets (Lunivia®)	2922	Treatment of insomnia, in adults, usually for short-term duration.	Not routinely available as not recommended for use in NHS Scotland, SMC 2922 https://scottishmedicines.org.uk/media/9966/eszopiclone-lunivia-non-sub-final-march-2026-for-website.pdf	21/04/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nemolizumab 30mg powder and solvent for solution for injection in pre-filled pen (Nemluvio®)	2833	For the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12years and older with a body weight of at least 30kg, who are candidates for systemic therapy. SMC restriction: for use in patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	2815	Treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2829	In combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026
sotatercept 45mg, 60mg powder and solvent for solution for injection (Winrevair®)	2923	In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity. SMC restriction: for use in patients with intermediate-low risk status on the European Society of Cardiology (ESC)/European Respiratory Society (ERS) four-strata risk rating system.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/04/2026